ТОП просматриваемых книг сайта:
Interventional Cardiology. Группа авторов
Читать онлайн.Название Interventional Cardiology
Год выпуска 0
isbn 9781119697381
Автор произведения Группа авторов
Жанр Медицина
Издательство John Wiley & Sons Limited
37 37 Hochman JS, Sleeper LA, White HD, et al. One‐year survival following early revascularization for cardiogenic shock. JAMA 2001; 285:190–2.
38 38 Hochman JS, Sleeper Lynn A., Webb John G., et al. Early Revascularization and Long‐term Survival in Cardiogenic Shock Complicating Acute Myocardial Infarction. JAMA 2006; 295:2511–5.
39 39 Thiele H, Desch S, Piek JJ, et al. Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT‐SHOCK trial. Am Heart J 2016; 172:160–9.
40 40 Thiele H, Akin I, Sandri M, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017; 377:2419–32.
41 41 Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non‐ST‐segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48:931–8.
42 42 Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON‐TIMI 38). Am Heart J 2006; 152:627–35.
43 43 Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357:2001–15.
44 44 Savonitto S, Ferri LA, Piatti L, et al. Comparison of Reduced‐Dose Prasugrel and Standard‐Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation 2018; 137:2435–45.
45 45 Pepe M, Cafaro A, Paradies V, et al. Time‐dependent benefits of pre‐treatment with new oral P2Y12 ‐inhibitors in patients addressed to primary PCI for acute ST‐elevation myocardial infarction. Catheter Cardiovasc Interv 2019; 93:592–601.
46 46 Gargiulo G, Esposito G, Avvedimento M, et al. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST‐Segment‐Elevation Myocardial Infarction: Primary Results of the FABOLUS‐FASTER Trial. Circulation 2020; 142:441–54.
47 47 Vlachojannis GJ, Vogel RF, Wilschut JM, et al. COMPARison of pre‐hospital CRUSHed vs uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. Am Heart J 2020; 224:10–6.
48 48 Vlachojannis GJ, Wilschut JM, Vogel RF, et al. Effect of Pre‐Hospital Crushed Prasugrel Tablets in Patients with STEMI Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Circulation 2020, Oct 14.
49 49 Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361:1045–57.
50 50 Montalescot G, van 't Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST‐segment elevation myocardial infarction. N Engl J Med 2014; 371:1016–27.
51 51 Koul S, Smith JG, Götberg M, et al. No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST‐Segment‐Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2018; 11:e005528.
52 52 Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE‐18 Study. Circulation 2016; 134:1603–12.
53 53 Schüpke S, Neumann F‐J, Menichelli M, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med 2019; 381:1524–34.
54 54 Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non‐ST‐Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016; 134:e123‐55.
55 55 Hahn J‐Y, Song YB, Oh J‐H, et al. 6‐month versus 12‐month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART‐DATE): a randomised, open‐label, non‐inferiority trial. The Lancet 2018; 391:1274–84.
56 56 Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug‐eluting stent implantation in ST‐elevation myocardial infarction (DAPT‐STEMI): randomised, multicentre, non‐inferiority trial. BMJ 2018; 363:k3793.
57 57 Luca G de, Damen SA, Camaro C, et al. Final results of the randomised evaluation of short‐term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new‐generation stent (REDUCE trial). EuroIntervention 2019; 15:e990–e998.
58 58 Kim B‐K, Hong S‐J, Cho Y‐H, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA 2020; 323:2407–16.
59 59 Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High‐Risk Patients after PCI. N Engl J Med 2019; 381:2032–42.
60 60 Khan SU, Singh M, Valavoor S, et al. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug‐Eluting Stents: A Systematic Review and Network Meta‐Analysis. Circulation 2020; 142:1425–36.
61 61 Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012; 34:44–55.
62 62 Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368:1303–13.
63 63 Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361:2330–41.
64 64 Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361:2318–29.
65 65 Franchi F, Rollini F, Rivas A, et al. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST‐Segment‐Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation 2019; 139:1661–70.
66 66 Grimfjärd P, Lagerqvist B, Erlinge D, et al. Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J Cardiovasc Pharmacother 2019; 5:151–7.
67 67 Ubaid S, Ford TJ, Berry C, et al. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Thromb Haemost 2019; 119:1171–81.
68 68 Zeymer U, Wienbergen H. A review of clinical trials with eptifibatide in cardiology. Cardiovasc Drug Rev 2007; 25:301–15.
69 69 Luca G de, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST‐segment elevation myocardial infarction: a meta‐analysis of randomized trials. JAMA 2005; 293:1759–65.
70 70 Montalescot G, Antoniucci D, Kastrati A,